Literature DB >> 31068316

[Establishment of a stable HEK293T cell line with c.392G>T (p.131G>V) mutation site knockout in G6PD gene using CRISPR/Cas9 technique].

Yanxia Zhou1, Weiwei Hui1, Hongyang Zhang1, Lin Zou1, Penghui Zhang1.   

Abstract

OBJECTIVE: To establish a stable HEK293T cell line with c.392G>T (p.131G>V) mutation site knockout in G6PD gene using CRISPR/Cas9 technique.
METHODS: We designed 4 pairs of small guide RNA (sgRNA) for G6PD c.392G>T(p.131G>V) mutation site, and constructed exogenous PX458 plasmids expressing Cas9-sgRNA. The plasmids were transfected into HEK293T cells, and the cells expressing GFP fluorescent protein were separated by flow cytometry for further culture. After verification of the knockout efficiency using T7 endonuclease Ⅰ, the monoclonal cells were screened by limiting dilution and DNA sequencing to confirm the knockout. We detected the expressions of G6PD mRNA and protein and examined functional changes of the genetically modified cells.
RESULTS: We successfully constructed the Cas9-sgRNA exogenous PX458 plasmid based on the c.392G>T(p.131G>V) mutation site of G6PD gene. The editing efficiency of the 4 pairs of sgRNA, as detected by T7E1 enzyme digestion, was 6.74%, 12.36%, 12.54% and 2.94%. Sanger sequencing confirmed that the HEK293T cell line with stable knockout of G6PD c.392G>T(p.131G>V) was successfully constructed. The genetically modified cells expressed lower levels of G6PD mRNA and G6PD protein and showed reduced G6PD enzyme activity and proliferative capacity and increased apoptosis in response to vitamin K3 treatment.
CONCLUSIONS: We successfully constructed a stable HEK293T cell model with G6PD gene c.392G>T(p.131G>V) mutation site knockout to facilitate future study of gene repair.

Entities:  

Keywords:  CRISPR/Cas9; G6PD; HEK293T cells; gene knockout

Mesh:

Substances:

Year:  2019        PMID: 31068316      PMCID: PMC6765671          DOI: 10.12122/j.issn.1673-4254.2019.03.10

Source DB:  PubMed          Journal:  Nan Fang Yi Ke Da Xue Xue Bao        ISSN: 1673-4254


  30 in total

1.  Cytomegalovirus colitis and haemolytic anaemia in a glucose-6-phosphate dehydrogenase-deficient immunocompetent patient.

Authors:  Raymond Farah; Wisam Sbeit; Faris Nassar; Hector Cohen; Ron Reshef
Journal:  Eur J Gastroenterol Hepatol       Date:  2003-09       Impact factor: 2.566

2.  CRISPR/Cas9-mediated gene editing in human zygotes using Cas9 protein.

Authors:  Lichun Tang; Yanting Zeng; Hongzi Du; Mengmeng Gong; Jin Peng; Buxi Zhang; Ming Lei; Fang Zhao; Weihua Wang; Xiaowei Li; Jianqiao Liu
Journal:  Mol Genet Genomics       Date:  2017-03-01       Impact factor: 3.291

3.  Prevention of muscular dystrophy in mice by CRISPR/Cas9-mediated editing of germline DNA.

Authors:  Chengzu Long; John R McAnally; John M Shelton; Alex A Mireault; Rhonda Bassel-Duby; Eric N Olson
Journal:  Science       Date:  2014-08-14       Impact factor: 47.728

4.  Production of Gene-Corrected Adult Beta Globin Protein in Human Erythrocytes Differentiated from Patient iPSCs After Genome Editing of the Sickle Point Mutation.

Authors:  Xiaosong Huang; Ying Wang; Wei Yan; Cory Smith; Zhaohui Ye; Jing Wang; Yongxing Gao; Laurel Mendelsohn; Linzhao Cheng
Journal:  Stem Cells       Date:  2015-05       Impact factor: 6.277

Review 5.  The global prevalence of glucose-6-phosphate dehydrogenase deficiency: a systematic review and meta-analysis.

Authors:  Ella T Nkhoma; Charles Poole; Vani Vannappagari; Susan A Hall; Ernest Beutler
Journal:  Blood Cells Mol Dis       Date:  2009-02-23       Impact factor: 3.039

Review 6.  Glucose-6-phosphate dehydrogenase deficiency.

Authors:  M D Cappellini; G Fiorelli
Journal:  Lancet       Date:  2008-01-05       Impact factor: 79.321

Review 7.  Glucose-6-Phosphate Dehydrogenase Deficiency.

Authors:  Lucio Luzzatto; Caterina Nannelli; Rosario Notaro
Journal:  Hematol Oncol Clin North Am       Date:  2016-04       Impact factor: 3.722

Review 8.  G6PD deficiency in Latin America: systematic review on prevalence and variants.

Authors:  Wuelton M Monteiro; Fernando F A Val; André M Siqueira; Gabriel P Franca; Vanderson S Sampaio; Gisely C Melo; Anne C G Almeida; Marcelo A M Brito; Henry M Peixoto; Douglas Fuller; Quique Bassat; Gustavo A S Romero; Oliveira Maria Regina F; Lacerda Marcus Vinícius G
Journal:  Mem Inst Oswaldo Cruz       Date:  2014-08-19       Impact factor: 2.743

9.  High Efficiency Gene Correction in Hematopoietic Cells by Donor-Template-Free CRISPR/Cas9 Genome Editing.

Authors:  Duran Sürün; Joachim Schwäble; Ana Tomasovic; Roy Ehling; Stefan Stein; Nina Kurrle; Harald von Melchner; Frank Schnütgen
Journal:  Mol Ther Nucleic Acids       Date:  2017-11-10       Impact factor: 8.886

Review 10.  G6PD deficiency: a classic example of pharmacogenetics with on-going clinical implications.

Authors:  Lucio Luzzatto; Elisa Seneca
Journal:  Br J Haematol       Date:  2013-12-28       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.